Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 14 | 2026 | 881 | 2.530 |
Why?
|
| Fever | 3 | 2021 | 122 | 1.400 |
Why?
|
| Candidiasis | 2 | 2023 | 40 | 1.260 |
Why?
|
| Vancomycin | 3 | 2024 | 80 | 1.130 |
Why?
|
| Drug Utilization | 2 | 2018 | 65 | 1.010 |
Why?
|
| Antimicrobial Stewardship | 4 | 2021 | 27 | 0.980 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2020 | 87 | 0.850 |
Why?
|
| Febrile Neutropenia | 2 | 2021 | 16 | 0.810 |
Why?
|
| Pharmacy | 1 | 2023 | 10 | 0.790 |
Why?
|
| Organ Transplantation | 3 | 2023 | 306 | 0.770 |
Why?
|
| Staphylococcal Infections | 2 | 2023 | 286 | 0.750 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 86 | 0.740 |
Why?
|
| Clostridium Infections | 1 | 2024 | 132 | 0.730 |
Why?
|
| Meningitis, Aseptic | 1 | 2022 | 6 | 0.710 |
Why?
|
| Enterovirus | 1 | 2022 | 16 | 0.710 |
Why?
|
| Enterovirus Infections | 1 | 2022 | 25 | 0.710 |
Why?
|
| Bacteremia | 3 | 2020 | 111 | 0.700 |
Why?
|
| Meningitis | 1 | 2022 | 22 | 0.700 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2022 | 56 | 0.680 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 195 | 0.670 |
Why?
|
| Respiratory Tract Infections | 3 | 2018 | 111 | 0.650 |
Why?
|
| Neutropenia | 2 | 2020 | 211 | 0.640 |
Why?
|
| Stem Cell Transplantation | 1 | 2021 | 194 | 0.630 |
Why?
|
| Hypersensitivity | 1 | 2020 | 166 | 0.580 |
Why?
|
| Drug Packaging | 1 | 2018 | 7 | 0.570 |
Why?
|
| Medication Errors | 1 | 2019 | 36 | 0.570 |
Why?
|
| Neutrophils | 1 | 2020 | 346 | 0.560 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 73 | 0.560 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 412 | 0.530 |
Why?
|
| Guideline Adherence | 2 | 2017 | 250 | 0.520 |
Why?
|
| Candida | 1 | 2016 | 20 | 0.480 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2020 | 977 | 0.480 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 6 | 0.480 |
Why?
|
| Retrospective Studies | 15 | 2026 | 10962 | 0.480 |
Why?
|
| Blood Culture | 1 | 2016 | 16 | 0.470 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 37 | 0.460 |
Why?
|
| Pneumococcal Vaccines | 1 | 2015 | 32 | 0.440 |
Why?
|
| Oseltamivir | 1 | 2015 | 9 | 0.440 |
Why?
|
| Streptococcus pneumoniae | 1 | 2015 | 50 | 0.430 |
Why?
|
| Pneumococcal Infections | 1 | 2015 | 44 | 0.430 |
Why?
|
| Pneumonia | 1 | 2016 | 195 | 0.420 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 74 | 0.420 |
Why?
|
| Viruses | 1 | 2015 | 64 | 0.420 |
Why?
|
| Social Media | 1 | 2016 | 118 | 0.420 |
Why?
|
| Electronic Health Records | 1 | 2019 | 442 | 0.420 |
Why?
|
| Virus Diseases | 1 | 2015 | 83 | 0.410 |
Why?
|
| Humans | 36 | 2026 | 98135 | 0.410 |
Why?
|
| Education, Medical | 1 | 2016 | 229 | 0.400 |
Why?
|
| Antiviral Agents | 2 | 2021 | 369 | 0.390 |
Why?
|
| Escherichia coli | 1 | 2016 | 572 | 0.380 |
Why?
|
| Leukocyte Count | 2 | 2023 | 215 | 0.350 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 601 | 0.350 |
Why?
|
| Neoplasms | 3 | 2024 | 3334 | 0.340 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 685 | 0.340 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 342 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2658 | 0.330 |
Why?
|
| Surgical Wound Infection | 3 | 2020 | 250 | 0.320 |
Why?
|
| Aged | 18 | 2026 | 21760 | 0.320 |
Why?
|
| Recurrence | 2 | 2024 | 1254 | 0.300 |
Why?
|
| HIV Infections | 1 | 2019 | 1018 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 1109 | 0.280 |
Why?
|
| Female | 20 | 2026 | 51570 | 0.280 |
Why?
|
| Immunocompromised Host | 3 | 2024 | 139 | 0.270 |
Why?
|
| Child, Preschool | 3 | 2021 | 4006 | 0.260 |
Why?
|
| Transplant Recipients | 4 | 2023 | 182 | 0.250 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2017 | 68 | 0.240 |
Why?
|
| Geriatric Assessment | 2 | 2019 | 193 | 0.240 |
Why?
|
| Antifungal Agents | 2 | 2017 | 126 | 0.240 |
Why?
|
| Disease Management | 2 | 2019 | 377 | 0.230 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2026 | 90 | 0.220 |
Why?
|
| Laryngeal Neoplasms | 2 | 2016 | 89 | 0.220 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 338 | 0.220 |
Why?
|
| Chicago | 2 | 2021 | 1513 | 0.220 |
Why?
|
| Male | 17 | 2026 | 47109 | 0.220 |
Why?
|
| Child | 4 | 2021 | 7699 | 0.220 |
Why?
|
| Intensive Care Units | 2 | 2026 | 520 | 0.210 |
Why?
|
| Middle Aged | 15 | 2026 | 29442 | 0.210 |
Why?
|
| Pneumocystis carinii | 1 | 2023 | 5 | 0.200 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2023 | 18 | 0.200 |
Why?
|
| Adolescent | 5 | 2021 | 10097 | 0.200 |
Why?
|
| Transplantation, Homologous | 3 | 2021 | 1026 | 0.200 |
Why?
|
| Hospitalization | 2 | 2020 | 991 | 0.200 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2023 | 40 | 0.200 |
Why?
|
| Cross Infection | 1 | 2024 | 155 | 0.190 |
Why?
|
| Administration, Oral | 1 | 2024 | 674 | 0.190 |
Why?
|
| Multiplex Polymerase Chain Reaction | 3 | 2018 | 38 | 0.170 |
Why?
|
| Adult | 9 | 2023 | 29564 | 0.170 |
Why?
|
| Lactams | 1 | 2020 | 14 | 0.170 |
Why?
|
| beta-Lactams | 1 | 2020 | 16 | 0.160 |
Why?
|
| Syndrome | 1 | 2021 | 439 | 0.160 |
Why?
|
| Invasive Fungal Infections | 1 | 2020 | 10 | 0.160 |
Why?
|
| Medical Overuse | 1 | 2020 | 32 | 0.160 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2023 | 327 | 0.150 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 208 | 0.150 |
Why?
|
| Respiratory System | 1 | 2020 | 121 | 0.150 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2020 | 123 | 0.150 |
Why?
|
| Patient Transfer | 1 | 2020 | 113 | 0.150 |
Why?
|
| Bordetella Infections | 1 | 2018 | 5 | 0.140 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 7387 | 0.140 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 137 | 0.140 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2018 | 9 | 0.140 |
Why?
|
| Pharmacists | 1 | 2019 | 42 | 0.140 |
Why?
|
| Osmolar Concentration | 1 | 2018 | 166 | 0.140 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2018 | 12 | 0.140 |
Why?
|
| Glucocorticoids | 2 | 2023 | 370 | 0.140 |
Why?
|
| Medical Audit | 1 | 2018 | 43 | 0.140 |
Why?
|
| Risk Factors | 5 | 2024 | 6232 | 0.140 |
Why?
|
| Levofloxacin | 1 | 2018 | 9 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2025 | 3213 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1751 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 131 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 161 | 0.130 |
Why?
|
| Drug Compounding | 1 | 2018 | 99 | 0.130 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 126 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2019 | 418 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 132 | 0.130 |
Why?
|
| Drug Resistance, Microbial | 1 | 2016 | 63 | 0.120 |
Why?
|
| Itraconazole | 1 | 2016 | 13 | 0.120 |
Why?
|
| Empirical Research | 1 | 2016 | 20 | 0.120 |
Why?
|
| Triazoles | 1 | 2017 | 118 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2019 | 320 | 0.120 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 25 | 0.120 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 39 | 0.120 |
Why?
|
| Histocytochemistry | 1 | 2016 | 122 | 0.120 |
Why?
|
| DNA, Fungal | 1 | 2016 | 61 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 4026 | 0.120 |
Why?
|
| RNA, Ribosomal | 1 | 2016 | 66 | 0.120 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 9 | 0.120 |
Why?
|
| Autopsy | 1 | 2016 | 131 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2016 | 296 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2019 | 391 | 0.110 |
Why?
|
| Prognosis | 2 | 2021 | 4116 | 0.110 |
Why?
|
| Inpatients | 1 | 2019 | 369 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 65 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 237 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2531 | 0.110 |
Why?
|
| Laryngectomy | 1 | 2015 | 26 | 0.110 |
Why?
|
| Fungi | 1 | 2015 | 70 | 0.110 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2015 | 38 | 0.110 |
Why?
|
| Immunization, Secondary | 1 | 2015 | 42 | 0.110 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 87 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2015 | 39 | 0.110 |
Why?
|
| Cystectomy | 1 | 2015 | 124 | 0.110 |
Why?
|
| Advisory Committees | 1 | 2015 | 95 | 0.110 |
Why?
|
| Infant | 1 | 2021 | 3332 | 0.110 |
Why?
|
| Incidence | 2 | 2016 | 1777 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2015 | 142 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 1099 | 0.100 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 388 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2017 | 418 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 911 | 0.090 |
Why?
|
| Critical Illness | 2 | 2026 | 436 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 401 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 849 | 0.080 |
Why?
|
| United States | 3 | 2021 | 8193 | 0.080 |
Why?
|
| Time Factors | 2 | 2020 | 5576 | 0.080 |
Why?
|
| Lung | 1 | 2016 | 1407 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 3022 | 0.070 |
Why?
|
| Betacoronavirus | 2 | 2020 | 287 | 0.060 |
Why?
|
| Enterobacter cloacae | 1 | 2026 | 13 | 0.060 |
Why?
|
| Opportunistic Infections | 1 | 2024 | 57 | 0.050 |
Why?
|
| Pandemics | 2 | 2020 | 916 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2015 | 2680 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2026 | 206 | 0.050 |
Why?
|
| Europe | 1 | 2023 | 356 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 2013 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2025 | 541 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 31 | 0.040 |
Why?
|
| Alanine | 1 | 2021 | 82 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 19 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2024 | 421 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 79 | 0.040 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 25 | 0.040 |
Why?
|
| Coinfection | 1 | 2020 | 71 | 0.040 |
Why?
|
| Skilled Nursing Facilities | 1 | 2020 | 49 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 148 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 62 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 166 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 70 | 0.040 |
Why?
|
| Bordetella bronchiseptica | 1 | 2018 | 6 | 0.040 |
Why?
|
| Bordetella pertussis | 1 | 2018 | 17 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2018 | 115 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2018 | 215 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 889 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 395 | 0.030 |
Why?
|
| Dementia | 1 | 2020 | 227 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 358 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 236 | 0.030 |
Why?
|
| Serum | 1 | 2017 | 26 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2017 | 94 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2021 | 581 | 0.030 |
Why?
|
| Palliative Care | 1 | 2019 | 290 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 305 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1950 | 0.030 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 17 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2016 | 36 | 0.030 |
Why?
|
| Histoplasmosis | 1 | 2016 | 29 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1383 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 725 | 0.030 |
Why?
|
| Tablets | 1 | 2017 | 136 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 9713 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2017 | 527 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 7511 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1527 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 379 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1967 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 1013 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 2080 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 658 | 0.020 |
Why?
|